{"id":"W4406869966","doi":"10.1200/jco.2025.43.4_suppl.730","title":"GOBLET study: Results of the safety run-in for first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients treated with pelareorep + modified FOLFIRINOX +/- atezolizumab.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; FOLFIRINOX; Pancreatic ductal adenocarcinoma; Atezolizumab; Oncology; Internal medicine; Adenocarcinoma; Pancreatic cancer; Oxaliplatin; Cancer; Colorectal cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003131649,0.001404325,0.002178714,0.0005954201,0.000373867,0.00144888,0.0006918295,0.001462583,0.003452777],"category_scores_gemma":[0.002014584,0.0003732451,0.003901612,0.0004681776,0.0008890785,0.001295521,0.0007349331,0.002256238,0.0008777521],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001220446,"about_ca_system_score_gemma":0.001220122,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001224788,"about_ca_topic_score_gemma":0.002757149,"domain_scores_codex":[0.9990991,0.0004310593,0.00004413798,0.0001810056,0.0001265161,0.0001181485],"domain_scores_gemma":[0.9977629,0.0003691566,0.0005889998,0.0002400968,0.0001165164,0.000922276],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.880752,0.01277541,0.03893128,0.0008479172,0.006524054,0.0005241517,0.0002827972,0.001582193,0.01146958,0.0001965912,0.004752823,0.04136115],"study_design_scores_gemma":[0.4562235,0.4024559,0.1205957,0.000137284,0.005937642,0.001157078,0.0002048473,0.001257692,0.003259239,0.000405931,0.008278494,0.00008673035],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986298,0.003000189,0.0004011571,0.000520439,0.00009429862,0.001452265,0.006067831,0.0001246887,0.002041155],"genre_scores_gemma":[0.9727021,0.001825784,0.001305048,0.001180953,0.0002742001,0.001701868,0.01776866,0.0001014824,0.003139937],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003452777,"threshold_uncertainty_score":0.01656193,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1123088489511546,"score_gpt":0.449068490360593,"score_spread":0.3367596414094385,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}